Health
Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes – News-Medical.Net
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels
Reviewed by Emily Henderson, B.Sc.Sep 25 2020
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels.
The Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) found that the drug had a safety profile similar to that of other SGLT2 inhibitors and did not increase risk of maj…
-
Noosa News20 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
General23 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News19 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Business6 hours agoFord CEO makes stunning prediction about artificial intelligence